- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01506232
Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study
June 27, 2024 updated by: Gagan Joshi, Massachusetts General Hospital
The study aims to evaluate whether or not an EEG (a type of brain scan) is useful in diagnosing youth with either ADHD, BPD, ASD.
Youth with ADHD, BPD, ASD, and healthy controls (without ADHD, BPD, and ASD) will undergo an EEG, and the results will be analyzed using brain activity flow pattern analysis (BAFPA).
Twenty subjects with each disorder and twenty without any of the disorders under study (controls) will be evaluated.
All subjects will be comprehensively assessed with structured diagnostic interviews and neuropsychological testing.
All EEG analyses will be conducted under blind conditions.
Conditional probability and receiver operating characteristic (ROC) analyses will examine the diagnostic utility of the EEG scan, using the clinical diagnosis of ASD as the gold standard.
Study Overview
Status
Terminated
Study Type
Observational
Enrollment (Actual)
1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Cambridge, Massachusetts, United States, 02138
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 17 years (Child)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Youths ages 6-17 diagnosed with ADHD, ASD or BPD, or heathy controls.
Description
Inclusion Criteria:
- Male or female participants between 6 and 17 years of age.
- Right handedness.
- Fulfills DSM-IV-TR diagnostic criteria for ADHD, bipolar disorder (BPD I, II, or NOS), or ASD (autistic disorder, Asperger's disorder, or PDD-NOS) as established by clinical diagnostic interview and supported by K-SADS-E module for respective diagnoses.
- Subjects and their legal representative must have a level of understanding sufficient to communicate intelligently with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol.
- Subjects and their legal representative must be considered reliable.
- Each subject and his/her authorized legal representative must understand the nature of the study. The subject's authorized legal representative must sign an informed consent document and the subject must sign an informed assent document.
Exclusion Criteria:
- Investigator and his/her immediate family; defined as the investigator's spouse, parent, child, grandparent, or grandchild.
- I.Q. < 85
- History of active seizure disorder (as suggested by EEG suggestive of seizure activity and/or history of seizure in last 1 month)
- Pregnant or nursing females.
- Subjects with a medical condition that will either jeopardize subject safety or affect the scientific merit of the study, including:
- Organic brain disorders
- Uncorrected hypothyroidism or hyperthyroidism
- Renal or hepatic impairment.
- Clinically unstable psychiatric conditions or judged to be at serious suicidal risk
- Current diagnosis of schizophrenia
- History of substance use (except nicotine or caffeine) within past 3 months or urine drug screen positive for substances of abuse
- Significant sensory deficits such as deafness or blindness.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
ADHD
Youth diagnosed with ADHD.
|
|
ASD
Youth diagnosed with an Autism Spectrum Disorder (ASD).
|
|
BPD
Youth diagnosed with Bipolar Disorder.
|
|
Healthy Controls
Youth not diagnosed with any psychiatric/psychological disorder.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Agreement between clinical diagnoses and the results of brain activity flow pattern analysis (BAFPA).
Time Frame: Baseline
|
Subjects will undergo clinical diagnostic interviews and a comprehensive neuropsychological assessment, and then complete 1 EEG scan of approximately 1 hour.
The results of the BAFPA will be compared to the results of the clinical diagnostic interviews.
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Gagan Joshi, MD, Massachusetts General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Primary Completion (Actual)
November 1, 2012
Study Completion (Actual)
November 1, 2012
Study Registration Dates
First Submitted
January 5, 2012
First Submitted That Met QC Criteria
January 5, 2012
First Posted (Estimated)
January 9, 2012
Study Record Updates
Last Update Posted (Actual)
June 28, 2024
Last Update Submitted That Met QC Criteria
June 27, 2024
Last Verified
June 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010P000547
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeWithdrawnBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Vielight Inc.Not yet recruitingBipolar Disorder (BD) | Bipolar | Bipolar Disorder DepressionCanada
-
Xenon Pharmaceuticals Inc.RecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Xenon Pharmaceuticals Inc.Enrolling by invitationBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderUnited States
-
University of Texas Southwestern Medical CenterThe Texas Child Mental Health Care Consortium (TCMHCC)RecruitingBipolar Disorder Family Members | Bipolar Disorder (BD) | Bipolar Disorder I or II | Screening ToolUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of California, Los AngelesUniversity of Colorado, Denver; University of Pittsburgh; University of Cincinnati and other collaboratorsRecruitingAdolescents | Bipolar Disorder (BD) | Bipolar Disorder I or II | Bipolar Disorder NOS | Bipolar Spectrum DisorderUnited States
-
Babes-Bolyai UniversityRecruitingBipolar Disorder (BD)Romania
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil